Abnormal uterine bleeding
Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more
News
NICE U-turn on osteoporosis
11-Apr-08
NICE has reversed its decision to recommend alendronate as the only treatment option for osteoporosis in post-menopausal women.
A draft appraisal document issued by NICE now recommends second-line use of risedronate and etidronate in primary and secondary prevention of fractures.
The move follows concerns that GPs are being forced by PCTs to prescribe alendronate to patients with osteoporosis, despite one in four patients being unable to tolerate the drug, following NICE's announcement in June to only prescribe alendronate.
But the draft appraisal guidance from NICE now states that risedronate and etidronate can be used by women who cannot tolerate alendronate, subject to T-scores.
Prof David Reid, chairman of the National Osteoporosis Society medical board, said: ‘It is good news that NICE recognises that there is more than one drug out there for the treatment of osteoporosis, especially as many patients cannot tolerate alendronate.
However, he added: ‘Using T-scores to decide which treatment a patient should be given is clinically unworkable.'
Strontium ranelate is also recommended as an alternative treatment for women who cannot tolerate alendronate and risedronate, says NICE.
Quick search - use * for an abbreviated search, eg nico*
Tools
Healthcare Republic Forums
Hottest Topics
Quick search - use * for an abbreviated search, eg nico*
Latest Clinical Articles
Chronic low back pain
Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
Acute and sub-acute back pain
Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
MIMS Product News
New drug - Stelara
Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more
New high-strength nicotine patch
Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more
Prolonged-release aspirin
Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more
Comments
Rupen Kulkarni
11/04/2008
National Institute for Constant Errors based on cost-cutting has yet again backed down after we have been beating our heads against a wall for ages. Patients dont lie.
Only registered users may comment. Log in now or register for a free account.
There are problems with your form submission.
Please review the errors shown below.